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Abstract: Over the past few decades, different types of nucleoside phosphate-conjugates have been under 
extensive investigation due to their favorable molecular lability with interesting catalytic hydrolysis mechanisms, 
recognition as polymerase substrates, and especially for their development as antiviral/anticancer protide 
therapeutics. The antiviral conjugates such as nucleoside phosphoesters and phosphoramidates that were 
discovered and developed in the initial years have been well reviewed by the pioneers in the field. In the present review, we 
will discuss the basic chemical and biological principles behind consideration of some representative structural classes. We 
will also summarize the chemical and biological properties of some of the more recent analogues that were synthesized and 
evaluated in our laboratory and by others. This includes new principles for their application as direct substrates of 
polymerases, nucleobase-dependent catalytic and antiviral activity, and a plausible ‘prodrug of a prodrug’ strategy for 
tissue/organ-specific targeted drug delivery.   
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INTRODUCTION 
 The ability of unnatural nucleoside-based therapeutics to 
induce inhibition of uncontrolled cell proliferation or viral 
replication hinges upon stepwise phosphorylation into their 
active species, inhibition or binding of intracellular enzymes 
(polymerases, ribonucleotide reductase), incorporation into a 
growing DNA/RNA strand, and subsequent chain 
termination.[1] As most modified nucleoside substrates are 
very poor substrates for natural kinases, their phosphorylated 
metabolites are delivered to the cell, typically in the forms of 
lipophilic precursors.[2] In addition to overcome instability 
related to phosphatases and poor cell-penetration associated 
with negatively charged nucleotides, the use of 
pronucleotides can turn inactive nucleosides into potent 
compounds, generate broader-spectrum antivirals and in 
some cases circumvent drug resistance.[3-6] 
The current availability of effective prodrug systems for the 
uptake of nucleoside phosphates is primarily based on 
monophosphate conjugates (cycloSal, ProTides, SATE 
approaches), as the first kinase-mediated step is generally 
considered to be rate-limiting to nucleoside bioactivity. 
However, premature and/or site unspecific removal of the 
masking groups, substrate specificity of cellular enzymes 
involved in distal phosphorylation steps (NDPKs, creatine or 
3-phosphoglycerate kinases) and polymerase recognition 
remain relevant issues that need to be addressed to improve 
therapeutic activity.  
In this respect, on-going rational drug design has been 
principally devoted to further refining the physicochemical 
profile of these molecules through the “tuning” of the nature 
of the existing ligands and the pursuit of new protecting 
moieties relying on chemical rather than enzymatic 
dependant activation mechanisms. Further attention has been 
paid to the search for alternative nucleotide analogues that 
could bypass multiple anabolic steps or skip over the entire 
conventional kinase-mediated activation cascade.[7] The 
archetype prodrug candidate should in fact possess the 
ability to act as a direct substrate of the target polymerase. 
Apart from their therapeutic value, such strategies might 
prevent severe side effects and toxicity, which in some 
instances were observed due to the accumulation of the 
nucleoside monophosphates.[8-10] 
Exhaustive information on biological activities and mode of 
action of nucleoside phosphate prodrugs has been reviewed 
in a series of authoritative articles.[1, 11-15] A 
comprehensive treatment of all their preparative methods 
was also summarized in a recent review article.[16] Herein 
we will discuss those aspects that concern our contribution to 
this topic and relevant examples from the recent literature 
from other groups. We will focus on the application of 
prodrugs as direct substrates of polymerases, nucleobase-
dependent catalytic and antiviral activity together with a 
discussion of a possible ‘prodrug of a prodrug’ strategy for 
site-specific targeted drug delivery.   
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RECENT DEVELOPMENTS IN PRONUCLEOTIDES 
DESIGN: TOWARDS AN ANABOLIC 
DISENTANGLE?  
Antiviral prodrug approaches based on the conjugation of a 
nucleoside monophosphate to a α-amino acid moiety through 
a 5’-phosphoramidic bond are well documented in the 
literature. McGuigan and co-workers[17] and Wagner and 
co-workers,[18] have both made major contributions to the 
field. They have summarized the state of the art for aryloxy 
amino acid phosphoramidates diesters (ProTides) and 
amidate monoesters (aaNPs), respectively, in their reviews. 
Extensive mechanistic studies provided evidence for the 
nucleoside phosphoramidate deprotection to be initiated at 
the ester moiety by the action of a carboxyesterase-type 
enzyme or cathepsin A (Scheme 1). The resulting 
carboxylate 2 spontaneously undergoes an intramolecular 
rearrangement and displacement of the phenoxy group to 
form a five-membered cyclic anhydride intermediate 3, 
which, by reacting with a molecule of water gives a 
phosphoramidate diester 4.  In a subsequent stage, the 
successful release of the nucleotidic moiety into the cell 
relies on enzyme-catalysed selective P-N bond cleavage. 
 
Scheme 1. Intracellular activation of classical nucleoside 
phosphoramidates (ProTides) 
In line with this theme, our group disclosed that 
deoxynucleotide phosphoramidate monoester derivatives of 
L-aspartic acid (L-Asp) and L-hystidine (L-His) undergo 
enzymatic incorporation into a growing DNA chain in the 
presence of a DNA polymerase as HIV-1 Reverse 
Transcriptase (RT), while still retaining the requisite 
canonical base-pairing (Scheme 2).[19-21] Substrate design 
was driven by both geometric and electronic considerations, 
with the aim of achieving a correct alignment of the α-
phosphorus atom needed for the nucleotidyl transfer process 
in the enzyme active site as well as coordination by catalytic 
metal ions. The validity of this concept was illustrated 
through a systematic structure-substrate relationship study, 
designed to establish the influence of structural and chelating 
properties of other modified or unnatural amino acids for the 
induction of HIV-1 RT-catalyzed DNA synthesis.[22-27]  
 
 
 
Scheme 2. Molecular structure and mode of action of amino 
acid phosphoramidate nucleoside acting as triphosphate 
mimics (IDA = iminodiacetic acid, IDP = iminodipropionic 
acid). 
Remarkably, since the amino acid amidate moiety has 
proven able to mimic the natural pyrophosphate as leaving 
group, it seems more likely that prodrugs derived from such 
substrates can be directly processed by the polymerase, 
without the need of any extra metabolic steps common to 
other approaches. In view of the potential advantages 
associated with the structural features discussed above, a 
variety of aspartic acid based phenoxy phosphoramidate 
diesters of stavudine (d4T)[28] and 2’-C-methyl containing 
nucleosides[29] (Asp-ProTides) were synthesized and tested 
for potential anti-HIV-1 and HCV inhibitory activity. In 
nearly all reports on ProTides, L-alanine is most commonly 
used and has proved to be the best amino acid motif in terms 
of antiviral activity of the corresponding phosphoramidate. 
This observation matched dramatically greater rates of 
alanine ester hydrolysis in the first step of the activation 
pathway (Scheme 1) when compared to branched 
counterparts (leucine, valine, isoleucine).[30] Interestingly, 
the use of aspartic acid diesters in place of methyl alanine 
was marked in some cases by a significant improvement of 
activity, particularly when bulkier and more lipophilic alkyl 
groups were present as ester residues (n-butyl, amyl and 
isoamyl esters).[29] Although cytotoxicity occurred in the 
low micromolar range, selectivity index values remained 
favorable. 
Further, metabolism studies demonstrated that in the 
presence of liver esterases the hydrolysis of the β-carboxyl 
ester in the aspartate moiety preceded the cleavage of the 
ester at the α-position. Those events were followed by aryl 
displacement via neighboring group assistance of the α-
carboxylic group and the other typical steps needed to 
unmask the protecting groups. The nucleoside 
monophosphate is then released into the cell. Thus, it was 
envisaged that the β-carboxylic ester functionality could be 
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employed for guiding target-tissue drug delivery and that 
Asp-ProTides could thus be considered as ‘prodrugs of 
prodrugs’. Hypothetically, conjugation of the amino acid 
residue at the β-side chain with a biomolecule could facilitate 
hydrolysis in a specific tissue, where the β-carboxylic acid 
containing Asp-Protide would then undergo 
bioactivation.[29] 
In spite of the broad scope offered forth by nucleoside di- 
and tri-phosphate prodrugs ability to deliver the appropriate 
analogues to interact with polymerases, their utilization 
remains underexplored as an alternative delivery 
methodology as compared to monophosphates. This reflects 
an increased sensitivity of the pyrophosphate anhydride bond 
towards nucleophilic attack upon diminution of the negative 
charges. For instance, modifications of the β- or -
phosphorus atom based on diglycerides[31, 32] and 
cyclosaligenyl groups[33] (cycloSal) failed to deliver NDP 
owing to the preferential liberation of NMP. Analogues 
bearing liphophilic acyl chains were stable to P-βP 
hydrolytic cleavage in aqueous buffer, but underwent 
decomposition in biological media.[34] Of particular interest 
in this context are the recent findings by the Meier’s group 
challenging this knowledge. By introducing para-
(acyloxybenzyl) biolabile moieties of the β-phosphate 
moiety, it was possible to overcome the instability issues and 
the ineffective delivery associated with nucleoside 
diphosphates.[33, 35, 36] Such protecting groups convey to 
the corresponding prodrugs (DiPPro) high chemical stability 
at physiological pH, allowing for esterase-catalyzed or pH-
dependent selective hydrolysis of the acyl ester group to 
proceed faster than degradation of the pyrophosphate unit in 
cell extracts. This event triggers the 1,4-elimination of the 
benzyl group attached to phosphate function leading to a 
monosubstituted species that undergoes the same sequence a 
second time releasing NDP. 
 
Scheme 3. Mode of action of mixed nucleoside diphosphate 
prodrugs. 
The introduction of bulkier substituents onto the acyl moiety 
led to increased chemical stability, with a concurrent marked 
reduction in enzymatic substrate conversion to the desired 
NDP product. This resulted in higher amounts of the NMP 
formed by chemical hydrolysis. Based upon this knowledge, 
the authors developed a second generation of mixed 
diphosphate prodrugs of the type 8 (Scheme 3) combining 
alkyl residues with different lengths at the β-phosphate in 
order to achieve the optimal compromise between 
lipophilicity and fast activation, thus minimizing NMP 
formation.[37]  
Parallels may therefore be drawn between the second 
generation DiPPro approach developed by Meier and our 
Asp-ProTide methodology. Although conceptually diverse, 
they both attempt to combine different structural elements in 
a single conjugate that could thereby address simultaneously 
different objectives. 
 
REACTIVITY AND CHEMICAL DEGRADATION 
PATHS OF AMINO ACID NUCLEOSIDE 
PHOSPHORAMIDATES 
The unravelling of each chemical/enzymatic step involved in 
the process of prodrug release of the nucleoside phosphate 
into the cell can therefore provide valuable and predictive 
knowledge for tailoring analogues with superior 
physicochemical properties and therapeutic potency. 
However, the overall biological activity of a prodrug is 
dictated not only by the successful access to the 
corresponding active metabolite, but also by its inherent 
capacity to withstand undesired metabolic reactions. For 
example, amino acid nucleoside phosphoramidates should be 
sufficiently robust to undergo selective P-N bond cleavage 
while resisting the unnecessary release of the nucleoside by 
means of P-O bond cleavage. For a prodrug strategy based 
on aaNPs acting as direct inhibitors/substrates of a viral 
polymerase to be successful, such compounds should remain 
stable to both P-O and P-N bond cleavage before reaching 
the enzyme’s pocket. Additionally, the free carboxylic 
groups present in the amino acid moiety, critical for 
polymerase recognition and binding,[20] could, under certain 
conditions, induce unwanted chemical degradation reactions. 
 In view of these observations, recent studies[38, 39] were 
devoted to identify the elements that rule the selectivity for 
P-N/P-O bond hydrolysis. Determination of the chemical 
stability of those compounds at high temperatures is also 
important in view of the potential use as substrates for 
thermostable polymerases. As a result, the structural 
determination of amino acid phosphoramidates in the gas-
phase was investigated by electrospray ionization ESI-MS in 
both positive and negative ion modes and tandem mass 
spectrometry. The resulting fragmentation patterns provided 
important information for these studies.[40]  
Lonnberg et al. produced a first understanding of the 
solvolytic stability of amino acid phosphoramidate diesters 
by following the course of the hydrolytic breakdown of 
thymidine 5’-O-phenyl phosphoramidate conjugate with L-
alanine (L-Ala) methyl ester 11 at the temperature of 90 
ºC.[38, 41] A sequence of degradation events has been 
proposed in order to account for the observed distribution of 
reaction products summarized in Scheme 4 over a wide 
range of pH values.  
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Scheme 4. Accumulation of products upon acid and base-
catalysed hydrolysis of amino acid amidate ProTides.  
The key information to emerge from these studies was the 
identification of competing pathways accounting for the 
disappearance of the starting compound under acid-catalysed 
conditions. The first involves the nucleophilic displacement 
of the alanyl ester moiety to afford thymidine 5’-
phenylphosphate 12 as a result of P-N bond cleavage. 
Concurrently, the hydrolysed carboxylic function might also 
be involved in an intramolecular nucleophilic attack on the 
phosphorus. This would lead to either the nucleoside 5’-
monophosphate 13, following displacement of phenol and 
decomposition of cyclic phosphoramidate intermediate 22, 
or alternatively, to thymidine via the formation of an 
intermediate of type 23 (Scheme 5), rather than by 
dephosphorylation of 16.[42] Notably, the corresponding 
monoester analogue of 11 was found to undergo exclusively 
P-N bond rupture, in analogy with the behavior of related 
compounds.[43-45]  
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Scheme 5. Postulated intermediates involved in the acid-
catalysed intramolecular degradation of 14 (a = apical, e = 
equatorial). 
Under basic conditions compound 14 (Scheme 4) 
accumulated as the major product with no further 
degradation observed. The mechanism involved in the 
dominant reaction pathway, as shown in Scheme 6, has been 
rationalized to occur with the saponification of the alanyl 
methyl ester, followed by the intramolecular attack of the 
resulting carboxylate on the phosphorus atom. This would 
lead to the formation of the cyclic transition state 22 
followed by loss of the better leaving group - the phenoxide 
ion rather than the 5’-oxyanion of the nucleoside. The 
resulting cyclic anhydride is selectively hydrolysed at the P-
OPh bond owing to the apical position occupied by the 
endocyclic oxygen atom.[43, 46] Direct displacement of the 
phenoxide moiety by a hydroxide ion is a minor side reaction 
and most likely follows an SN2-type mechanism to give 
15.[47-51]  
 
 
Scheme 6. Dominant base-catalysed hydrolytic pathway for 
14. 
A comprehensive mechanistic study reported by our group 
provided important new insight into the principal structural 
factors that determine the thermal and chemical stability of 
aaNPs of type 7.[39, 52, 53] A comparison of the kinetics of 
hydrolysis under a set of conditions showed that the reaction 
occurred at a faster rate in acidic solutions (pH 5-7) and at 
higher temperatures (70 ºC), exhibiting a first-order 
dependence on both phosphoramidate[41, 54, 55] and 
hydronium ion[41, 54, 56] concentrations. As shown in 
Scheme 7 for L-Asp-NP, the presence of differentially 
protonated forms is conceivable in solution. Although 
protonation at the amide nitrogen is thought to be favored 
over protonation at the phosphoryl oxygen,[56-60] a 
tautomeric equilibrium most likely exists between the N- and 
O-protonated species.[43, 54] The hydrolysis of the P-N 
bond is believed to operate by an SN2 concerted mechanism. 
Engagement of the most stable N-protonated zwitterionic 
species 26 and a molecule of water in an associative-type 
transition state, would then lead to the final departure of the 
aspartyl moiety. 
Similarly, the mechanism involved in the P-O cleavage has 
been rationalized with the nucleophilic attack of the α-
carboxyl oxyanion at the phosphorus of the neutral 
phosphate species 24, although another possible pathway 
interprets the reaction as proceeding through the 
monoanionic phosphate 25. The five-membered trigonal 
bipyramidal phosphorane intermediate is thought to reflect 
the preference of the incoming oxygen nucleophile to adopt 
an apical position, thus forcing the nitrogen atom into an 
equatorial position and the nucleoside moiety in the 
remaining apical position. Proton transfer to the 5’-oxygen 
followed by departure of the nucleoside gives a cyclic 
phosphoramidate, which, upon hydrolysis, further rearranges 
to form the amino acid and organic phosphate products.  
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Scheme 7. Mechanisms for P/O versus P/N acid-catalyzed 
hydrolysis of L-Asp-dAMP. 
Examination of the kinetic and theoretical data collected for 
L-Asp-dAMP and related analogues revealed some 
interesting reactivity trends. The concomitant presence of a 
α- and β-carboxylic group in L-Asp-dAMP appeared to 
induce an accelerating effect on phosphoramidate hydrolysis 
(pH 6) in comparison with its glycine (α-COOH) and β-
alanine (β-COOH) counterparts, with a relative reactivity 
order Gly < β-Ala < Asp. When only a β-carboxyl group was 
present, selective P-N bond cleavage was observed, 
otherwise both P-N and P-O bond cleavage pathways were 
found to be operative, although to different extents. The 
extra group at the β-position further enhanced the 
destabilizing effect of the α-carboxyl group on the P-O bond. 
This outcome has been ascribed to an increased entropic 
contribution gained from the formation of a hydrogen bond 
between the 3’-OH of the sugar and the aspartyl residue (NH 
and/or β-carboxyl group), which might force the α-carboxyl 
moiety to adopt the required position for attack on the 
phosphorus atom.[53] 
With respect to the impact of the nature of the nucleobase on 
the reactivity, the estimation of hydrolysis rates following 
the replacement of adenine in L-Asp-dAMP with different 
deaza purines demonstrated a kinetic acceleration of P-O 
cleavage with the following order 3-deazaadenine < adenine 
< 7-deazaadenine < 1-deazaadenine. The compound Asp-1-
deazadAMP was found to be exceptionally prone to P-O 
bond hydrolysis even at low temperatures. The higher 
reactivity rates exhibited by 1-deaza and 7-deaza analogues 
compared to adenine were explained by a possible stabilizing 
role associated with the presence of a protonated N3 atom on 
the transition state involved in the intramolecular P-O bond 
decomposition pathway of the phosphoramidate species. 
Unlike the adenine-containing phosphoramidate, a favorable 
hydrogen-bonding interaction can occur owing to the rare 
syn-type conformation of the deaza nucleobases.[39]  
These findings open attractive possibilities for prodrug 
design since data on the hydrolysis reaction preferences (P-N 
vs. P-O) can be used as a predictive tool. For instance, it is 
reasonable to assume that 3-deaza phosphoramidate 
analogues would be more successful in delivering nucleoside 
monophosphates. This is due to their proclivity to P-N bond 
rupture when compared with 1- or 7-deaza compounds, 
which would instead afford the corresponding nucleosides 
through chemical degradation.   
 
THE ULTIMATE CHALLENGING ENDEAVOR IN 
PRODRUG THERAPY: TARGETED DRUG 
DELIVERY  
In spite of the encouraging progress that has been achieved 
in the last few years in this area of drug discovery, especially 
in terms of enhanced oral bioavailability and 
pharmacological potency, general effective methods for site 
specific targeting and the release of therapeutically relevant 
nucleosides/tides are still lacking. Directing drugs to specific 
tissues, organs or cellular compartments would be beneficial 
not only to reduce off-target adverse side effects but also to 
lower the effective dose required. For the most part, 
nucleoside prodrug molecules that to date have been 
proposed to overcome this problem were specifically 
designed so as to be selectively activated by a particular 
enzyme which expression is restricted to a specific tissue or 
to exploit differences in the redox environment of cellular 
spaces.  
In particular, HepDirect analogues are liver-selective cyclic 
prodrugs derived from 1-aryl substituted 1,3-propanyl 
phosphate (or phosphonate) esters. They represent the most 
prominent development within this context,[61] as 
demonstrated by their advancement to human clinical trials 
for the treatment of hepatitis B virus (HBV) infections, 
hepatocellular carcinoma and hypercholesterolemia.[62-64] 
They are characterized by a remarkable resistance to 
enzymatic activity in plasma and most tissues, with the 
exception of the liver, where they undergo oxidative 
cleavage at the benzylic carbon atom by a liver specific 
enzyme, namely cytochrome P450 (CYP3A). The 
biologically active compound is then released from the ring-
opened ketophosphate intermediate 32 by elimination of an 
unsaturated aryl ketone by-product 33 (Scheme 8). Although 
a detoxification process involving the enzyme glutathione S-
transferase is operative to help in the removal of 33 in the 
hepatocytes, nevertheless its high reactivity may constitute a 
significant concern in terms of unpredicted toxicity.  
 
Scheme 8. CYP450-catalysed liver activation of HepDirect 
prodrugs. 
Another novel approach follows a similar logic taking 
advantage of the reducing nature of the cytosolic 
environment, which represents one of the major cellular 
pools of glutathione (GSH).[65] Substituted 1,2-dithiane 
phosphate conjugates of type 35 undergo bioactivation in the 
cytosol by a “reduction-release” mechanism, in response to 
the high transmembrane GSH/GSSG redox potential 
difference between intra- and extracellular spaces. GSH-
promoted reduction of the disulphide bond is followed by 
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cyclodeesterification with release of a cyclic phosphodiester 
36 and formation of a transient thiirane derivative, which, 
upon cyclization, is converted to the stable 
tetrahydrothiophene species 39. Further enzymatic 
processing can then generate the monophosphate.  
 
Scheme 9. Cytosol-specific reductive bioactivation of 
cyclic-disulfide containing prodrugs. 
Strategies based on the conjugation of therapeutics with 
carrier molecules able to recognize tissue surface 
antigens[66, 67] or disease-associated biomarkers, as well as 
liposome encapsulation[68, 69] and the use of diverse 
nanocarriers may constitute valuable tools to ensure high 
local accumulation of the parent drug.[70] Nevertheless, they 
are not often associated with an increased therapeutic index, 
primarily due to inadequate exchange across the vascular 
endothelial barrier and slow rates of payloads release relative 
to drug clearance from the system.[71] At the present time, 
the development of drug conjugates as delivery method has 
also been delayed by concerns related to production costs, 
unpredictable immune responses and therapeutic 
formulation.  
Regardless, the increased amount of research being 
conducted in the field of aptamer-drug conjugates points to 
their potential to solve the challenges related to targeted 
drug-delivery, especially owing to their intrinsic high affinity 
and specificity for molecular recognition. This assumption is 
supported by a very recent report, which described the 
incorporation of multiple units of the nucleoside analogue 5-
fluoro-2’-deoxyuridine into an aptamer specifically binding 
the cell surface interleukin-6 receptor, the deregulation of 
which is connected with malignancies.[72] Once 
internalized, the aptamer is subsequently transferred to a 
lysosome, responsible for its nucleotidyl degradation with 
consequent liberation of the nucleoside that can then be 
further phosphorylated. The resulting monophosphate is 
endowed with cytostatic activity through inhibition of 
thymidylate synthase. It can be reasoned therefore, that this 
proof of principle will not be confined to anticancer 
nucleosides, but holds promise for applications as an 
important delivery strategy in the antiviral field. 
Finally, as we discussed earlier, a functionalized amino acid, 
specifically derivatization of aspartic acid at the β-position, 
might offer forth a great versatility for accessing 
bioconjugates which could serve a double purpose of tuning 
the bioavailability while targeting drug delivery (‘prodrug of 
a prodrug’). Even though at this moment this rationale seems 
rather speculative, it does allow one to draw a number of 
predictions for the requirements that must be fulfilled but 
that could be experimentally probed to further expand this 
concept.  
CONCLUSION 
 Several new principles for the design of new nucleoside 
conjugates as potential antivirals have been proposed over 
the last years, some of which have been described in this 
review. One major breakthrough would be the availability of 
nucleoside conjugates that are direct substrate for 
polymerases, circumventing the necessity for intracellular 
activation of the modified nucleosides by the kinases. 
Another interesting approach is the use of ProTides in which 
the masking group is removed in vivo by a chemical, rather 
than an enzymatic mechanism. In the event that the base 
moiety of the nucleoside is involved in prodrug degradation, 
the approach will become base dependent. This would make 
the prodrug approach less reliant on the presence of 
degrading enzymes, and thus, more predictable. Tissue 
targeting could also be achieved by synthesizing ‘prodrugs 
of prodrugs’, in which one entity is responsible for targeting 
a particular tissue and the other entity for transmembrane 
transport and intracellular activation. None of these 
approaches however, has reached the level of clinical 
research, but they may prove to inspire chemists to design 
new conjugates and further study their chemical and 
biological properties. 
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